Opus Genetics is trading 5% up now at $4.03, with the move appearing driven by speculative positioning ahead of three-month topline data from the OPGx-BEST1 Cohort 1 study, expected during the second week of September 2026.
- Shares gained 5.80% to $3.83 on September 1.
- The XBI sector ETF is up 2.75%, supporting biotech sentiment and adding momentum.
- No new company announcement dated September 2 was identified, leaving the catalyst anticipatory rather than confirmed.